On December 29, 2022, AMA CPT released the latest cycle of new PLA codes, representing codes submitted for review on October 1, 2022. The codes just released will be effective on April 1, 2023.
Two codes were revised (0022U, 0095U), two deleted (0324U, 0325U for cancer cell culture), and 23 new codes from 0364U to 0386U were created. Codes 0022U are Oncomine Dx (the Thermo Fisher FDA-approved NGS test) and 0095U Elisa analysis of esophageal biomarkers.
Among many others, Mayo got a neurofilament light chain plasma test (0361U) and Quest got a large tumor panel (523 DNA, 55 RNA). These and other codes from 0355U up, will enter the CMS pricing meetings in June 2023.
See the full report here:
https://www.ama-assn.org/system/files/cpt-pla-codes-long.pdf
AMA publishes new PLA codes on a rolling basis each quarter, dropping those codes that appear in the annual CPT publication. The CY2023 AMA code book runs up to 0354U, so during 2023, each quarterly "new PLA" publication will start with 0355U and end with the newest code of the quarter.
